EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”

Yanbai Li iD, Shanshan Huo, Zhe Yin, Zuguang Tian, Fang Huang, Peng Liu iD, Yue Liu iD, Fei Yu iD

mBio · 2024

DOI: 10.1128/mbio.00175-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Yanbai Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Key Laboratory of Analysis and Control of Zoonotic Pathogenic Microorganism, Hebei Wild Animal Health Center, College of Life Sciences, Hebei A…. Hauptthemen laut MEDLINE: Antiviral Agents, Clinical Trials as Topic, Drug Development, Influenza, Human. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and mortality rates. Currently, the influenza drugs recommended by the Food and Drug Administration are oseltamivir, zanamivir, peramivir, and baloxavir marboxil. These recommended antivirals are currently effective for major subtypes of IVs as the compounds target conserved domains in neuraminidase or polymerase acidic (PA) protein. However, this trend may gradually change due to the selection of antiviral drugs and the natural evolution of IVs. Therefore, there is an urgent need to develop drugs related to the treatment of influenza to deal with the next pandemic. Here, we summarized the cutting-edge research in mechanism of action, inhibitory activity, and clinical efficacy of drugs that have been approved and drugs that are still in clinical trials for influenza treatment. We hope this review will provide up-to-date and comprehensive information on influenza antivirals and generate hypotheses for screens and development of new broad-spectrum influenza drugs in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsClinical Trials as TopicDrug DevelopmentInfluenza, HumanHumansDibenzothiepinsMorpholinesOrthomyxoviridaePyridonesTriazinesZanamivir

Stichwörter der Autor:innen

adverse eventantiviral drugsclinical drugsinfluenza virusmechanism of action

Substanzen

Antiviral AgentsbaloxavirDibenzothiepinsMorpholinesPyridonesTriazinesZanamivir

Autor:innen und Institutionen

  • Hebei Key Laboratory of Analysis and Control of Zoonotic Pathogenic Microorganism, Hebei Wild Animal Health Center, College of Life Sciences, Hebei Agricultural University, Baoding, China.
  • Department of High-Tech Development, Baoding City Science and Technology Bureau, Baoding, China.
  • Epidemic Prevention Laboratory, Tongzhou District Center For Animal Disease Control and Prevention, Beijing, China.
  • Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA.

ORCID-Profile: Yanbai Li, Peng Liu, Yue Liu, Fei Yu

Zitieren

APA

Li, Y., Huo, S., Yin, Z., Tian, Z., Huang, F., Liu, P., Liu, Y., & Yu, F. (2024). Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”. mBio. https://doi.org/10.1128/mbio.00175-24

Vancouver

Li Y, Huo S, Yin Z, Tian Z, Huang F, Liu P, et al. Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”. mBio. 2024. doi:10.1128/mbio.00175-24

BibTeX
@article{Li2024,
  author = {Li, Yanbai and Huo, Shanshan and Yin, Zhe and Tian, Zuguang and Huang, Fang and Liu, Peng and Liu, Yue and Yu, Fei},
  title = {Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.00175-24}
}
Kostenlos starten →